Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.37 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30746852 | 1.00 | NR4A2 (0.40) | NR4A2CYP3A4P2RY6P2RY14TTBK1 | |
| SCHEMBL5741696 | 0.89 | ACLY (0.36) | TTBK1TTBK2ACLYQPCTMKNK1 | |
| SCHEMBL1041938 | 0.89 | MAPT (0.43) | NR4A2ACLYMEN1MAPTKMT2A | |
| SCHEMBL1077717 | 0.87 | NR4A2 (0.40) | NR4A2CYP3A4P2RY6P2RY14TTBK1 | |
| SCHEMBL1040015 | 0.86 | MAP2K1 (0.46) | NR4A2 | |
| SCHEMBL1077501 | 0.85 | MAPT (0.41) | NR4A2CYP3A4MEN1ALDH1A1MAPT | |
| SCHEMBL30886595 | 0.84 | MAP2K1 (0.47) | NR4A2ACLYALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1037390 | 0.84 | MAP2K1 (0.47) | NR4A2ACLYALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8059115 | 0.82 | MKNK1 (0.40) | NR4A2CYP3A4P2RY6P2RY14TTBK1 | |
| SCHEMBL1040943 | 0.79 | CYP2C9 (0.42) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024003942-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SELUMETINIB SULFATE | NATCO PHARMA LIMITED (IN) | 2024-01-04 | — | — | WO | disclosed |
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | SHENZHEN TARGETRX, INC. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | SHENZHEN TARGETRX, INC. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-3712133-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | Shenzhen TargetRx, Inc. (CN) | 2020-09-23 | — | — | EP | disclosed |
| EP-3000810-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | ARRAY BIOPHARMA INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9562017-B2 | Hydrogen sulfate salt | AsrtaZeneca AB (SE) | 2017-02-07 | — | — | US | disclosed |
| EP-3000810-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | Array Biopharma, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20160024018-A1 | Novel Hydrogen Sulfate Salt | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2016-01-28 | — | — | US | disclosed |
| US-9156795-B2 | Hydrogen sulfate salt | ARRAY BIOPHARMA, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2275102-B1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2015-07-29 | — | — | EP | disclosed |
| WO-2007076245-A2 | NOVEL HYDROGEN SULFATE SALT | ARRAY BIOPHARMA INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | REN, BRAF, CDK4 | NR4A2 1961/4885CYP3A4 222/4885P2RY6 1016/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | NR4A2 2705/4885CYP3A4 807/4885P2RY6 1557/4885 |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | BRAF, CCNI, NRAS | NR4A2 2733/4885CYP3A4 989/4885P2RY6 1115/4885 |
| US-20160024018-A1 | Novel Hydrogen Sulfate Salt | SUDS3, SLC9A1, SLC5A1 | NR4A2 3381/4885CYP3A4 3634/4885P2RY6 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.